Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus()

AIM: To evaluate the efficacy/safety of canagliflozin twice daily (BID) compared with placebo in patients with type 2 diabetes mellitus (T2DM) on metformin. METHODS: In this 18-week, randomized, double-blind, placebo-controlled study, patients (N = 279) at 60 centers in 7 countries received canaglif...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Transl Endocrinol
Hlavní autoři: Qiu, Rong, Capuano, George, Meininger, Gary
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2014
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685027/
https://ncbi.nlm.nih.gov/pubmed/29159083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcte.2014.04.001
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky